LAUSR

Objectives: to prove the effect of Garcinea Mangostana L as potent antiinflammatory, anti-diabetic,anticholesterol in highrisk cardiovascular patients Methods: A randomized,Singleblind,placebo-controlled clinical trial was conducted in 90 adults with highrisk cardiovascular score which were determined based on Framingham criteria, age 50–70y. Patients were devided into two group. One group given 2520 mg/day Garcinia mangostana Linn extracts in 3 divided dose for 90 days and the other group given placebo. Parameters were Nitrit Oxide (NO), IL-1,IL-6, TNF &agr;,MDA,HDL,LDL,Total Cholesterol, Fasting Blood Glucose, and HbA1C measured at baseline and after 90 day's of treatment. Results: At 90 days, After administration of Garcinia mangostana L extract, we found that there was a significance decreasing in Nitric Oxide (NO) compared with placebo ( − 6.69 ± 15,59 uMvs2,9 ± 15.0 uM; P = 0.007). We found that The plasma IL-6, IL-1,MDA,and HsCRP concentration was significantly decrease compared with placebo ( − 90.85 ± 99.29,3pg/ml vs50,25 ± 140,52 pg/ml; P = 0.000; − 12.08 ± 12,1 pg/ml vs10.3 ± 13.4 pg/ml; P = 0.000; − 156 ± 374,39 pg/ml vs54,5 ± 343,52 pg/ml;P = 0,012; − 130,5 ± 106,3 pg/ml vs-17,1 ± 71,7 pg/ml;P = 0,000; respectively). Interstingly, There was no difference in plasma level of TNF&agr; compared with placebo. We observed significance decrase compared with placebo in Cholestrol total,LDL, and HbA1c ( − 12.52 ± 37.31 mg/dl vs1,36 ± 26,25 mg/dl; P = 0.05; − 18,29 ± 28.6 mg/dl vs1,8 ± 18,5 mg/dl; P = 0.003;; − 0,29. ± 1,1 vs0,25 ± 0,78; P = 0,012; respectively). There was no difference in HDL, TG, and Fasting Blood Glucose. Conclusion: Garcinia mangostana L extract has anti-inflammatory effect due to reduce plasma level of IL-1,IL-6,MDA, and HsCRP. Administration of Garcinia Mangostana L extract was able to reduce Cholestrol total, LDL and HbA1c significantly.